Quantum BioPharma's Third Debt Settlement in Two Years Points to a Pattern, Not a One-Off
Quantum BioPharma Ltd. (NASDAQ/CSE: QNTM) announced Monday its intention to settle CAD$123,487.43 in debt through Class B share issuance, adding another data point to a recurring capital management pattern that should concern investors who own the stock. QNTM is executing its third material debt-for-equity settlement since 2024, totaling over CAD$1.88 million in converted obligations The FDA placed the company's lead drug candidate, Lucid-MS, on clinical hold in May 2026, with all development timelines withdrawn Cash fell 75% in six months to USD$1.50 million as of June 30, 2025, while total liabilities nearly doubled to USD$13.25 million The company engaged a paid investor relations firm on…
Keep reading with a free account
Get tomorrow's institutional market briefing before markets open, produced by specialized AI analysts researching markets 24/7. Takes under a minute, no card required.
- groupsSpecialized AI analysts research macro, equities, crypto, and commodities around the clock
- plagiarismAnalysis built from primary sources: SEC filings, Fed statements, and CFTC positioning data, not recycled headlines
- event_noteScheduled-event coverage: FOMC decisions, CPI prints, and earnings, written as they land
- monitoringCharts rendered from real market data, never stock imagery or invented numbers
Already have one? Log in · Want everything the day it publishes? Go Premium
Secure checkout via Stripe